Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein...

Full description

Bibliographic Details
Main Authors: Takahiro Wakasaki, Ryuji Yasumatsu, Muneyuki Masuda, Toranoshin Takeuchi, Tomomi Manako, Mioko Matsuo, Rina Jiromaru, Ryutaro Uchi, Noritaka Komune, Teppei Noda, Takashi Nakagawa
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
biomarker
chemotherapy
C-reactive protein
distant metastasis
head and neck squamous cell carcinoma
neutrophil to lymphocyte ratio
Online Access:https://www.mdpi.com/2072-6694/12/8/2299

Internet

https://www.mdpi.com/2072-6694/12/8/2299

Similar Items